New Life Sciences Crowdfunding Platform Opens To UK Investors
Date posted:
News
A crowdfunding platform dedicated to life sciences has announced that it is now open to investors from the UK, carefully selecting high quality scientific investment opportunities for life sciences innovators and investors.
Capital Cell – based in Barcelona – has thus far raised more than €4.4 million for research and development in life sciences like genomics, medical devices, biotechnology, therapeutics and genomics, Crowdfund Insider reports.
UK director of the company Dr Laura Ferguson explained that before now private life sciences investment has usually only been available to those with lots of money to invest and with extensive technical expertise.
“Whilst investing in early stage companies will always involve significant risks, Capital Cell’s unique screening process and new investment platform opens up opportunities to everyone. If the companies are successful in achieving their goals the financial rewards for investors can be significant and the social impact can affect the lives of millions,” she went on to say.
Current investment opportunities include OvuSense, a fertility monitoring platform with 24-hour advance real-time ovulation prediction. It apparently doubles the chances of conception in comparison to other methods.
Or there’s Absynth Biologics, which has currently raised £362,001 in funds with a target of £650,000. The company’s antigens harness both antibody and T cell responses, with no marketed vaccines for the primary targets of MRSA and C. difficile at the moment.
The life sciences industry is fast growing where investment is concerned, giving companies not only the chance to benefit financially but also socially as well, knowing that they’re influencing the future of the world.
For help with life science consulting, get in touch with the Voicentric team today.